AOD-9604 Handling Guide: Common Mistakes to Avoid
Most handling advice for research peptides is written generically. The practices below are the ones that specifically matter for AOD-9604 — including the mistakes it is unusually easy to make with this compound.
Overview
Let the vial warm to room temperature before opening, swirl rather than shake, and keep reducing agents and high-pH buffers away from it. Label portions with the date and liquid used.
What AOD-9604 actually is
AOD-9604 is a 16-part lab-made peptide copied from the very end of human growth hormone, with one extra building block (tyrosine) added at the front and a single sulfur-sulfur bridge holding it in a loop. Animal studies from the early 2000s looked at how it affects fat metabolism, and a later rabbit study looked at joint cartilage. It was developed in Australia as an obesity drug candidate, but that programme was stopped in 2007 and it was never approved as a medicine.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Bench practices for AOD-9604
- Let the vial reach room temperature before opening.
- Add diluent gently down the vial wall and swirl; do not vortex.
- Keep reducing agents (DTT, TCEP, β-mercaptoethanol) and alkaline buffers away from the stock.
- Label aliquots with reconstitution date and diluent.
The chemistry behind these practices
- Disulfide exchange (scrambling) and formation of disulfide-linked dimers, accelerated above about pH 8.
- Reduction of the Cys7–Cys14 bridge by reducing agents, giving an open-chain form 2 Da heavier.
- Slow glutamine deamidation over long storage.
Storage summary
What AOD-9604 is studied for
Heffernan et al. (Endocrinology 2001) compared hGH and AOD9604 over 14 days in obese mice and in β3-adrenergic-receptor knockout mice. Both raised the repressed β3-AR expression in obese mice, but neither changed body weight or lipolysis in the knockout mice over the long-term protocol, leading the authors to conclude the lipolytic actions were not mediated directly through β3-AR.
Ng et al. (Horm Res 2000) studied oral administration of AOD9604 in obese Zucker rats, reporting reduced body-weight gain and increased adipose lipolytic activity, and — unlike intact hGH — no impairment of insulin sensitivity on euglycaemic clamp.
Stier et al. (J Endocrinol Metab 2013) pooled six randomised, double-blind, placebo-controlled trials and reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism, and no anti-AOD9604 antibodies in tested participants. The same development programme did not show a clinically meaningful weight outcome.
Kwon and Park (Ann Clin Lab Sci 2015) gave intra-articular AOD9604, with or without hyaluronic acid, in a collagenase-induced knee osteoarthritis model in rabbits and scored cartilage morphology, histology and lameness.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000.
- Stier H, Vos E, Kenley D Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013.
- Kwon DR, Park GY Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical & Laboratory Science. 2015.
- Browse current AOD-9604 literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More AOD-9604 reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Lab Handling reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
AOD-9604 is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.